The Changing Landscape of 1L Treatment of ALK-Positive Advanced NSCLC: What Does the ALEX Data Show?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

GRACE

cancergrace.org

Podcast Series
Targeted Therapies in Lung Cancer 2023
ASCO® 2023
Lung Cancer OncTalk
Blood Cancer OncTalk
2022 Melanoma Video Library
OncTalk 2022
ASCO Lung Review 2022
ASCO and ESMO Lung Recap
2021 Targeted Therapies Patient Forum
COVID-19
Lung
Hematologic Oncology
Head and Neck
Brain
Palliative
Genitourinary
General
Breast

Playback speed

10 seconds

The Changing Landscape of 1L Treatment of ALK-Positive Advanced NSCLC: What Does the ALEX Data Show?

By GRACE FEATURING Alice Shaw

0 views

January 17, 2019

Comments 0

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Lung

04:01

GRACE

Lung Resection in Early Stage NSCLC: An Overview

Feat. C. Jeffrey Yang

05:58

GRACE

Future Goals of mNSCLC Treatment

Feat. P. Iyengar

06:13

GRACE

The NRG-LU Trial: Maintenance Systemic Therapy vs. Local Consolidati…

Feat. P. Iyengar

06:14

GRACE

Using Radiation to Improve Outcomes and QoL in Patients With mNSCLC

Feat. P. Iyengar

02:41

GRACE

Staging Disease: How Oncologists Stage NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang

03:19

GRACE

Biomarkers in NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang

06:09

GRACE

Perioperative vs. Preoperative Surgery in NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang

03:25

GRACE

Antibody Drug Conjugates and How They Are Used in NSCLC

Feat. L. Bazhenova

02:36

GRACE

ADC Treatment in NSCLC

Feat. L. Bazhenova

03:15

GRACE

Bispecific Antibodies in Lung Cancer

Feat. L. Bazhenova

02:52

GRACE

Amivantamab in 1L Advanced NSCLC With EGFR exon 20 Insertion Mutatio…

Feat. L. Bazhenova

05:47

GRACE

Treatment Options for EGFR+ NSCLC

Feat. I. Dagogo-Jack, N. Vokes

03:42

GRACE

Surgical Options for Stage IV NSCLC With Brain Metastases: 60 y/o Wo…

Feat. I. Dagogo-Jack, J. Reuss

06:02

GRACE

Neoadjuvant Chemo +/- Nivo for Patients With Early Stage NSCLC: Case…

Feat. I. Dagogo-Jack, J. Reuss

03:21

GRACE

Treating Stage III NSCLC: Case-Based Panel Discussion

Feat. I. Dagogo-Jack, K. Arbour

03:44

GRACE

How Oncologists Stage Disease - Case-Based Panel Discussion: 50 y/o …

Feat. I. Dagogo-Jack, J. Reuss, N. Vokes, K. Arbour

09:37

GRACE

Is Broad NGS the Standard of Care in Advanced NSCLC?

Feat. I. Dagogo-Jack, M. Marmarelis, A. Sacher, A. Hegde

05:27

GRACE

Neoadjuvant Therapy vs. Adjuvant Therapy in NSCLC: What Is the Futur…

Feat. J. West, E. Rodriguez, R. Shah, N. Duma

05:38

GRACE

Surgical vs. Nonsurgical Treatment in Early NSCLC

Feat. J. West, E. Rodriguez, R. Shah, N. Duma

07:28

CancerGRACE

Early Stage NSCLC: PD-L1 and Durvalumab

Feat. J. West, E. Rodriguez, R. Shah, N. Duma

04:35

GRACE

Testing in Potentially Resectable & Unresectable Locally Advance…

Feat. J. West, E. Rodriguez, R. Shah, N. Duma

22:49

CancerGRACE

The Need for Broad Molecular Testing for Driver Mutations in NSCLC

Feat. J. Gainor

26:08

GRACE

NSCLC Frontline Therapy for Uncommon Mutations: Overview of RET, NTR…

Feat. J. Gainor

06:15

CancerGRACE

Expert Discussion on Targeted Therapy for mNSCLC: Can ALK Inhibitors…

Feat. J. West

18:10

GRACE

A Case of a NSCLC KRAS 71 y/o Female With Underlying Autoimmune Cond…

Feat. S. Liu, J. Brahmer, B. Levy

15:42

CancerGRACE

Expert Analysis of 1L EGFR+ Advanced NSCLC Options: 1st Gen Gefitini…

Feat. J. Weiss

10:33

GRACE

Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Res…

Feat. Z. Piotrowska

18:15

CancerGRACE

Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon …

Feat. Z. Piotrowska

05:41

GRACE

ASCO Expert Discussion on Malignant Pleural Mesothelioma: Does Durva…

Feat. J. West, H. Yu, D. Spigel

05:47

GRACE

ASCO Roundtable on 2L Malignant Pleural Mesothelioma: How Encouragin…

Feat. J. West, H. Yu, D. Spigel

10:25

CancerGRACE

IO for Unresectable Stage 3 NSCLC: Does Durvalumab Help Patients? Wh…

Feat. M. Das

08:13

CancerGRACE

2020 ASCO Highlights on RT+ Chemo in LS-SCLC: Is There a Difference …

Feat. J. West, H. Yu, D. Spigel

16:22

GRACE

2020 ASCO ADAURA Trial Update on Adjuvant Osimertinib in EGFR+ NSCLC…

Feat. H. Yu, D. Spigel, J. West

11:28

CancerGRACE

2020 ASCO Update on 1L Advanced NSCLC: Is Nivo + Ipi + Limited Cours…

Feat. H. Yu, D. Spigel, J. West

11:22

CancerGRACE

2020 ASCO Update on Advanced NSCLC: What Is the Role for Nivolumab/I…

Feat. H. Yu, D. Spigel, J. West

09:02

CancerGRACE

2020 ASCO Update on MET/RET+ NSCLC: How Promising Are Capmatinib &am…

Feat. H. Yu, D. Spigel, J. West

08:25

CancerGRACE

2020 ASCO Update on HER2+ NSCLC: Is There a Promising Clinical Activ…

Feat. H. Yu, D. Spigel, J. West

12:16

CancerGRACE

2020 ASCO Update on EGFR+ NSCLC: Does Upfront SBRT to Sites at Diagn…

Feat. H. Yu, D. Spigel, J. West

08:16

CancerGRACE

ASCO 2020 Updates on PD-L1 NSCLC: Is Tiragolumab+Atezo Beneficial fo…

Feat. J. West, H. Yu, D. Spigel

05:32

GRACE

2020 Updates on SCLC: Have We Progressed in the Treatment of Relapse…

Feat. T. Owonikoko

05:16

CancerGRACE

Liquid Biopsy in NSCLC: Does Adding Liquid Biopsy to Tissue Testing …

Feat. C. Aggarwal

06:45

GRACE

SCLC Updates: What Are the Leading Immunotherapy Options?

Feat. S. Liu

05:38

GRACE

Expert Discussion on mNSCLC: What Are the Leading Treatment Options …

Feat. S. Liu

05:45

GRACE

2020 Update on Molecular Abnormalities in NSCLC: How Do MET Exon 14 …

Feat. J. Bauml

05:56

GRACE

The Role of IO for NSCLC Patients With Driver Mutations: What Data D…

Feat. B. Levy

07:43

CancerGRACE

2020 Update on Targeted Therapies in NSCLC PD-L1 Expression: What Ar…

Feat. M. Das

07:55

GRACE

Non-Small Cell Lung Cancer: Is Immunotherapy Safe for Frail Patients…

Feat. M. Gubens

05:13

GRACE

Does Immunotherapy Have Activity in Malignant Pleural Mesothelioma?

Feat. M. Das

06:15

CancerGRACE

Non-Small Cell Lung Cancer: How Does a Positive HER2 Mutation Affect…

Feat. J. West, J. Riess, S. Padda

06:03

GRACE

ALK+ NSCLC With High PD-L1. What Is the First Line Treatment for Pot…

Feat. J. West, J. Riess, S. Padda

06:00

CancerGRACE

What Is the Importance of MET Amplification Level in EGFR+ NSCLC Wit…

Feat. C. McCoach, H. Wakelee, J. West

03:45

GRACE

NSCLC EGFR Mutation Treated With Tagrisso: Progression While on Trea…

Feat. C. McCoach, H. Wakelee, J. West

07:30

CancerGRACE

NSCLC EGFR Mutation and the FLAURA Trial: Is There a Difference in D…

Feat. C. McCoach, H. Wakelee, J. West

08:20

GRACE

EGFR + NSCLC: Is There a Place for Chemo and the Inclusion of Immuno…

Feat. J. West, H. Wakelee, C. McCoach

04:14

CancerGRACE

EGFR Mutation and High and High PD-L1 in NSCLC: What is the Role of …

Feat. C. McCoach, H. Wakelee, J. West

05:18

CancerGRACE

Non-Small Cell Lung Cancer: What Are the Recommended Treatments for …

Feat. C. McCoach, H. Wakelee, J. West

05:04

CancerGRACE

NSCLC With EGFR Mutation: What Are the Treatment Options with Oligop…

Feat. C. McCoach, H. Wakelee, J. West

07:12

CancerGRACE

NSCLC With EGFR Mutation: Is There a Place for Chemotherapy and an E…

Feat. C. McCoach, H. Wakelee, J. West

05:52

CancerGRACE

NSCLC With EGFR Uncommon Exon 20 Mutation: Suggested Treatments, Tar…

Feat. C. McCoach, H. Wakelee, J. West

04:20

GRACE

The Challenges of Potential Pneumonitis Following Durvalumab in Stag…

Feat. M. Gubens, J. West, M. Das

06:03

CancerGRACE

Would IO Be Beneficial for Stage 3 NSCLC Patient with PDL1-0 After S…

Feat. M. Gubens, J. West, M. Das

08:02

CancerGRACE

Best Schedule for Durvalumab for Older Patient in Stage 3 NSCLC Afte…

Feat. J. West, M. Gubens, M. Das

05:12

CancerGRACE

Unresectable NSCLC: What Is TMB and Does it Add Significant Benefit …

Feat. M. Gubens, J. West, M. Das

08:50

GRACE

Does Checkmate 227's Suggestion of an IO Combination of Ipi + N…

Feat. M. Gubens, J. West, M. Das

10:58

CancerGRACE

Should Molecular Tests Be Considered in Stage 3 NSCLC and Would Outc…

Feat. M. Gubens, J. West, M. Das

09:22

CancerGRACE

Case of 60 y/o Woman with ALK Positive Metastatic NSCLC: Approach to…

Feat. S. Padda, J. Riess, J. West

06:14

GRACE

Case of ALK Positive Patient with Asymptomatic Brain Metastases: Is …

Feat. S. Padda, J. Riess, J. West

09:45

GRACE

Treatment for NSCLC Patient Who Developed Resistance to ALK Inhibito…

Feat. S. Padda, J. Riess, J. West

11:11

GRACE

Is the Standard Treatment the Best Approach for Stage 3 Frail Patien…

Feat. M. Gubens, J. West, M. Das

06:43

CancerGRACE

Should We Continue the ALK Inhibitor in NSCLC Patient with Brain Met…

Feat. S. Padda, J. Riess, J. West

10:53

CancerGRACE

Is There a Role for Combination Therapies Like Chemo/Radio and IO fo…

Feat. S. Padda, J. Riess, J. West

09:53

GRACE

Stage 3 NSCLC - Standard Concurrent Chemo + Radiation, Followed by I…

Feat. M. Gubens, J. West, M. Das

11:27

CancerGRACE

Stage 3 NSCLC: Is the Standard Treatment of Chemo and Radiation Foll…

Feat. M. Gubens, J. West, M. Das

11:26

CancerGRACE

Case Based Discussion on Stage 3 NSCLC: Should We Do Molecular Tests…

Feat. M. Gubens, J. West, M. Das

05:24

GRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: How Promising is…

Feat. J. West, B. Levy, C. Aggarwal

05:32

CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Short Discussion…

Feat. J. West, B. Levy, C. Aggarwal

06:02

CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Circulating Tumo…

Feat. J. West, B. Levy, C. Aggarwal

05:53

CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Retrospective An…

Feat. J. West, B. Levy, C. Aggarwal

03:55

CancerGRACE

CancerGRACE's ASCO 2019 Update on Stage IV NSCLC: New Targets -…

Feat. J. West, B. Levy, C. Aggarwal

06:33

CancerGRACE

CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage …

Feat. J. West, B. Levy, C. Aggarwal

07:14

CancerGRACE

CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage …

Feat. J. West, B. Levy, C. Aggarwal

06:33

CancerGRACE

CancerGRACE's 2019 ASCO Highlights in Advanced NSCLC: What is t…

Feat. J. West, B. Levy, C. Aggarwal

06:38

CancerGRACE

CancerGRACE's 2019 ASCO Highlights on Adjuvant Afatinib in Stag…

Feat. J. West, B. Levy, C. Aggarwal

07:26

CancerGRACE

CancerGRACE's 2019 ASCO Highlights on Stage I NSCLC Adjuvant Ch…

Feat. J. West, B. Levy, C. Aggarwal

21:24

GRACE

Is There a Role for IO in EGFR+ Metastatic Lung Cancer?

Feat. H. Yu

47:56

CancerGRACE

Initial Treatment and Acquired Resistance in Advanced Lung Cancer &a…

Feat. J. Bauml, J. Sabari

21:58

CancerGRACE

Q&A on Targeted Therapies in Advanced Lung Cancer

Feat. J. Bauml

19:19

GRACE

Introduction to Next Generation Sequencing in Metastatic Lung Cancer…

Feat. J. Bauml

23:26

CancerGRACE

EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC

Feat. H. Yu

09:30

GRACE

Q&A on EGFR Initial Treatment and Acquired Resistance in Advance…

Feat. H. Yu

07:53

CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: First and Seco…

Feat. J. West

18:32

CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: Osimertinib vs…

Feat. J. West

17:04

CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: Dacomitinib, E…

Feat. J. West

17:10

CancerGRACE

Targeted Therapies in Advanced Lung Cancer: What is the Role of Rebi…

Feat. H. Borghaei

26:54

CancerGRACE

Discussion/Q&A on Targeted Therapies in Advanced Lung Cancer

Feat. H. Borghaei

15:23

GRACE

Targeted Therapies in Metastatic NSCLC: Liquid Biopsies as a New Opt…

Feat. C. Aggarwal

02:13

CancerGRACE

Immunotherapy in Stage lll NSCLC - The Pacific Trial and Imfinzi

Feat. K. Kelly

01:54

CancerGRACE

Tumor Mutation Burden in Patients with Non-Squamous NSCLC: Current S…

Feat. S. Patel

02:41

CancerGRACE

Evolving Standards for Molecular Testing in Advanced NSCLC

Feat. S. Patel

02:05

CancerGRACE

Combinations of Immunotherapy Agents in Advanced NSCLC: Current Stat…

Feat. S. Patel

02:17

GRACE

The Basics of Managing Immune-Mediated Side Effects in NSCLC

Feat. S. Patel

03:50

CancerGRACE

What Should Patients With Rapid Progression in Advanced NSCLC Throug…

Feat. J. West

04:46

GRACE

"Consolidation" Radiation After a Good Response to First L…

Feat. J. West

06:57

CancerGRACE

Chemotherapy and Immunotherapy Combinations in Advanced Non-Squamous…

Feat. J. West

05:39

CancerGRACE

Chemo Immuno Therapy Combinations in Advanced Squamous NSCLC

Feat. J. West

07:13

CancerGRACE

Does Immunotherapy Work in Patients with Driver Mutations Like EGFR …

Feat. J. West

04:09

CancerGRACE

EGFR TKI Gilotrif(Afatinib) in Metastatic Squamous NSCLC

Feat. V. Velcheti

04:24

CancerGRACE

Lung Cancer Immunotherapy- Is There Anything Better than PDL1

Feat. V. Velcheti

03:20

GRACE

MET as a Target in Advanced NSCLC

Feat. V. Velcheti

04:33

CancerGRACE